DS-8895a 1 mg/kg + DS-8895a 3 mg/kg + DS-8895a 10 mg/kg
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Malignant Solid Tumor
Conditions
Malignant Solid Tumor, Metastatic EphA2 Positive Cancer
Trial Timeline
Dec 9, 2014 → Sep 8, 2016
NCT ID
NCT02252211About DS-8895a 1 mg/kg + DS-8895a 3 mg/kg + DS-8895a 10 mg/kg
DS-8895a 1 mg/kg + DS-8895a 3 mg/kg + DS-8895a 10 mg/kg is a phase 1 stage product being developed by Daiichi Sankyo for Malignant Solid Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT02252211. Target conditions include Malignant Solid Tumor, Metastatic EphA2 Positive Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02252211 | Phase 1 | Completed |
Competing Products
20 competing products in Malignant Solid Tumor